Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a significant stock price increase, with a 5% rise on March 27, reaching 53.32 CNY per share, and a cumulative increase of 6.82% over three consecutive days [1][5]. Company Overview - Tiger Med, officially known as Hangzhou Tiger Medical Technology Co., Ltd., was established on December 15, 2004, and went public on August 17, 2012. The company is located in Hangzhou, Zhejiang Province [1][5]. - The main business involves providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6]. Revenue Composition - The revenue composition of Tiger Med is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other supplementary services for 2.19% [6]. Fund Holdings - Three funds under Founder Fubon hold a total of 443,100 shares of Tiger Med, with a floating profit of approximately 1.1255 million CNY based on the stock price increase [2][7]. - The specific funds and their holdings are as follows: - Founder Fubon Jin Lifang One-Year Holding Mixed Fund (019226) holds 381,500 shares, representing 3.88% of the fund's net value [3][8]. - Founder Fubon Emerging Growth Mixed Fund (008602) holds 47,500 shares, representing 3.72% of the fund's net value [4][9]. - Founder Fubon Xincheng 12-Month Holding Mixed Fund (015514) holds 14,100 shares, representing 3.66% of the fund's net value [4][9].